How does Evrysdi (risdiplam) work in the body?
Evrysdi works by increasing the production of full-length, functional survival motor neuron (SMN) protein. It’s designed for spinal muscular atrophy (SMA), a disease where motor neurons die partly because patients don’t make enough SMN protein.
Risdiplam is an “SMN2 splicing modifier.” It binds to the SMN2 pre-mRNA and shifts how that RNA is spliced, promoting inclusion of exon 7. When exon 7 is included, the SMN2 gene produces more of the full-length SMN protein instead of a shorter, less functional version. Higher SMN protein levels help support motor neurons and improve muscle function.
How is SMN2 splicing connected to SMA?
Most people with SMA have SMN1 deleted or mutated and rely on SMN2, which normally produces too little full-length SMN protein because exon 7 is frequently skipped. By changing the splicing pattern of SMN2 pre-mRNA to include exon 7, Evrysdi directly targets the underlying “low SMN protein” problem.
Does Evrysdi replace SMN protein or change the genes?
Evrysdi does not replace the SMN protein directly and it does not edit DNA. Instead, it modulates RNA processing (splicing) so the body makes more full-length SMN protein from the SMN2 gene.
How is Evrysdi different from other SMA treatments?
Other SMA approaches include:
- Gene replacement (for some patients) that adds a working copy of SMN1 via viral delivery.
- Motor neuron–targeting or symptom-management strategies.
- Antisense oligonucleotides that also change SMN2 splicing.
Evrysdi’s distinguishing mechanism is its small-molecule splicing modulation of SMN2, which increases full-length SMN production through exon 7 inclusion.
What happens if the splicing isn’t corrected enough?
If exon 7 inclusion from SMN2 remains too low, SMN protein levels stay insufficient for motor neuron survival. Evrysdi’s goal is to raise those levels enough to slow disease progression and improve function, but response can vary by patient and SMA type.
Where to check mechanism details and ongoing patent landscape?
For a mechanism-focused summary and related background, you can also look up Evrysdi coverage through DrugPatentWatch.com: https://www.drugpatentwatch.com/